{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:20:00Z","timestamp":1755224400520,"version":"3.43.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.soc.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:52:29Z","timestamp":1725929549000},"page":"69-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Metastatic Anal Cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Joseph Do Woong","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devansh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toufic","family":"El-Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimalan","family":"Pathma-Nathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Wei Tatt","family":"Toh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.soc.2024.08.001_bib1","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/curroncol30030246","article-title":"Anal cancer: the past, present and future","volume":"30","author":"Gondal","year":"2023","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.soc.2024.08.001_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/codi.14569","article-title":"A\u00a0systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer","volume":"21","author":"Ko","year":"2019","journal-title":"Colorectal Dis"},{"issue":"9","key":"10.1016\/j.soc.2024.08.001_bib3","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.08.001_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/0284186X.2021.1999497","article-title":"Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases \u2013 a report from the Danish Anal Cancer Group","volume":"61","author":"Wind","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.soc.2024.08.001_bib5","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/jco.2012.30.15_suppl.4060","article-title":"Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal","volume":"30","author":"Eng","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2024.08.001_bib6","first-page":"756591","article-title":"Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm?","volume":"2012","author":"Dewdney","year":"2012","journal-title":"ISRN Oncol"},{"issue":"7","key":"10.1016\/j.soc.2024.08.001_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/DCR.0000000000001114","article-title":"The American Society of Colon and Rectal Surgeons clinical practice guidelines for anal squamous cell cancers (Revised 2018)","volume":"61","author":"Stewart","year":"2018","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"10.1016\/j.soc.2024.08.001_bib8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.6004\/jnccn.2023.0030","article-title":"Anal carcinoma, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Benson","year":"2023","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2024.08.001_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1463-1318.2010.02493.x","article-title":"Anal cancer. position statement of the Association of Coloproctology of Great Britain and Ireland introduction","volume":"13","author":"Scholefield","year":"2011","journal-title":"Colorectal Dis"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2024.08.001_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1463-1318.2010.02495.x","article-title":"Initial management through the anal cancer multidisciplinary team meeting","volume":"13","author":"Renehan","year":"2011","journal-title":"Colorectal Dis"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2024.08.001_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1463-1318.2010.02499.x","article-title":"Follow up","volume":"13","author":"Myint","year":"2011","journal-title":"Colorectal Dis"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2024.08.001_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1463-1318.2010.02496.x","article-title":"Staging and management of inguinal nodes","volume":"13","author":"Branagan","year":"2011","journal-title":"Colorectal Dis"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2024.08.001_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1463-1318.2010.02497.x","article-title":"Chemoradiotherapy in anal cancer","volume":"13","author":"Kronfli","year":"2011","journal-title":"Colorectal Dis"},{"issue":"1","key":"10.1016\/j.soc.2024.08.001_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.soc.2016.07.008","article-title":"Metastatic anal cancer and novel agents","volume":"26","author":"Morris","year":"2017","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"10.1016\/j.soc.2024.08.001_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9343(89)80702-8","article-title":"Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal","volume":"87","author":"Ajani","year":"1989","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.soc.2024.08.001_bib16","first-page":"861","article-title":"[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]","volume":"86","author":"Faivre","year":"1999","journal-title":"Bull Cancer"},{"issue":"10","key":"10.1016\/j.soc.2024.08.001_bib17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Glynne-Jones","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.08.001_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/02841869309083882","article-title":"Treatment of relapsing anal carcinoma","volume":"32","author":"Tanum","year":"1993","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.soc.2024.08.001_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000361051","article-title":"Carboplatin and paclitaxel treatment is effective in advanced anal cancer","volume":"87","author":"Kim","year":"2014","journal-title":"Oncology"},{"issue":"23","key":"10.1016\/j.soc.2024.08.001_bib20","first-page":"e002996","article-title":"Recent advances in the management of anal cancer","volume":"11","author":"Upadhyay","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"22","key":"10.1016\/j.soc.2024.08.001_bib21","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2024.08.001_bib22","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mdt396","article-title":"DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2024.08.001_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975356","article-title":"Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.08.001_bib24","first-page":"e39","article-title":"FOLFCIS treatment and genomic correlates of response in advanced anal squamous cell cancer","volume":"18","author":"Mondaca","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.soc.2024.08.001_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000446107","article-title":"Successful treatment of metastatic anal canal adenocarcinoma with mFOLFOX6\u00a0+ Bevacizumab","volume":"9","author":"Matsunaga","year":"2016","journal-title":"Case Rep Oncol"},{"issue":"5","key":"10.1016\/j.soc.2024.08.001_bib26","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.3390\/curroncol30050343","article-title":"Immunotherapy in anal cancer","volume":"30","author":"Dhawan","year":"2023","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.soc.2024.08.001_bib27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.soc.2024.08.001_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.soc.2024.08.001_bib29","doi-asserted-by":"crossref","first-page":"100529","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"A\u00a0phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.soc.2024.08.001_bib30","doi-asserted-by":"crossref","first-page":"102373","DOI":"10.1016\/j.ctrv.2022.102373","article-title":"Immunotherapy in advanced anal cancer: Is the beginning of a new era?","volume":"105","author":"Ciardiello","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.soc.2024.08.001_bib31","doi-asserted-by":"crossref","first-page":"e002996","DOI":"10.1136\/jitc-2021-002996","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study","volume":"9","author":"Lonardi","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.soc.2024.08.001_bib32","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.514","article-title":"403MO Atezolizumab in combination with bevacizumab for patients with unresectable\/metastatic anal cancer","volume":"31","author":"Morris","year":"2020","journal-title":"Ann Oncol"},{"issue":"30","key":"10.1016\/j.soc.2024.08.001_bib33","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase i\/ii study","volume":"37","author":"Doran","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.08.001_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T\u00a0cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.soc.2024.08.001_bib35","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A\u00a0phase ii study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2024.08.001_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.soc.2024.08.001_bib37","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.18632\/oncotarget.27536","article-title":"A\u00a0phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent\/recurrent loco-regional or metastatic anal cancer","volume":"11","author":"Eng","year":"2020","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.soc.2024.08.001_bib38","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.18632\/oncotarget.2563","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.soc.2024.08.001_bib39","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.amjsurg.2020.08.016","article-title":"Role of metastasectomy for liver metastasis in stage IV anal cancer","volume":"221","author":"Goldner","year":"2021","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.soc.2024.08.001_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.6004\/jnccn.2018.7085","article-title":"Definitive pelvic radiotherapy and survival of patients with newly diagnosed metastatic anal cancer","volume":"17","author":"Wang","year":"2019","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"12","key":"10.1016\/j.soc.2024.08.001_bib41","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/cncr.32017","article-title":"Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: a National Cancer Database review","volume":"125","author":"Abdelazim","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.soc.2024.08.001_bib42","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cell.2009.12.013","article-title":"Tumor self-seeding: bidirectional flow of tumor cells","volume":"139","author":"Leung","year":"2009","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.soc.2024.08.001_bib43","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1158\/0008-5472.CAN-12-4488","article-title":"Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model","volume":"73","author":"Newton","year":"2013","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.soc.2024.08.001_bib44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.soc.2024.08.001_bib45","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soc.2024.08.001_bib46","unstructured":"National Cancer Institute (NCI), EA2176: phase 3 clinical trial of carboplatin and paclitaxel +\/- nivolumab in metastatic anal cancer patients. ClinicalTrials.Gov identifier NCT04444921, 2020, National Cancer Institute (NCI). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04444921."},{"key":"10.1016\/j.soc.2024.08.001_bib47","doi-asserted-by":"crossref","first-page":"935383","DOI":"10.3389\/fonc.2022.935383","article-title":"POD1UM-303\/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma","volume":"12","author":"Rao","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.soc.2024.08.001_bib48","doi-asserted-by":"crossref","first-page":"678","DOI":"10.6004\/jnccn.2023.7031","article-title":"Prognostic and predictive markers for patients with anal cancer","volume":"21","author":"Holliday","year":"2023","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.soc.2024.08.001_bib49","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/jitc-2020-001395","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies","volume":"8","author":"Strauss","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.soc.2024.08.001_bib50","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.21037\/apm-22-1390","article-title":"Palliative care in colorectal and anal malignancies from diagnosis to death","volume":"12","author":"Karlekar","year":"2023","journal-title":"Ann Palliat Med"},{"issue":"2","key":"10.1016\/j.soc.2024.08.001_bib51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.21037\/apm.2020.02.06","article-title":"Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center","volume":"9","author":"Ahn","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"1","key":"10.1016\/j.soc.2024.08.001_bib52","doi-asserted-by":"crossref","first-page":"21068","DOI":"10.1038\/s41598-022-23928-w","article-title":"Palliative care reduces emergency room visits and total hospital days among patients with metastatic HPB and GI cancers","volume":"12","author":"Billiot","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.soc.2024.08.001_bib53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/1049909116689459","article-title":"Outpatient palliative care and aggressiveness of end-of-life care in patients with metastatic colorectal cancer","volume":"35","author":"Lee","year":"2018","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.soc.2024.08.001_bib54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jss.2019.04.009","article-title":"Timing of palliative care in colorectal cancer patients: does it matter?","volume":"241","author":"Delisle","year":"2019","journal-title":"J\u00a0Surg Res"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:17:33Z","timestamp":1755011853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320724000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1055320724000528"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2024.08.001","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Metastatic Anal Cancer","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}